PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA

PREVENTION OF HEPATITIS B VIRUS CARRIER STATE IN INFANTS ACCORDING TO MATERNAL SERUM LEVELS OF HBV DNA

235 infants of HBeAg-carrier mothers in Hong Kong were assigned to four study groups. Groups I, II, and III received hepatitis-B (HB) vaccine at birth and at 1, 2, and 6 months. Group I also received seven monthly injections of HB immunoglobulin (HBIg), and group II received one HBIg injection at bi...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 1989-02, Vol.333 (8635), p.406-410
Hauptverfasser: Ip, HenriettaM.H., Wong, VivianC.W., Lelie, P.Nico, Kuhns, MaryC, Reesink, HenkW
Format: Artikel
Sprache:eng
Schlagworte:
Babies
Biological and medical sciences
Deoxyribonucleic acid
DNA
Hepatitis
Hepatitis B
Human viral diseases
Infants
Infectious diseases
Medical sciences
Vaccines
Viral cardiopathies
Viral diseases
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:235 infants of HBeAg-carrier mothers in Hong Kong were assigned to four study groups. Groups I, II, and III received hepatitis-B (HB) vaccine at birth and at 1, 2, and 6 months. Group I also received seven monthly injections of HB immunoglobulin (HBIg), and group II received one HBIg injection at birth. Group III received vaccine only and group IV received placebo for both vaccine and HBIg. At the age of 3 years, all infants of the three treatment groups were significantly protected against the HB virus (HBV) carrier state compared with the placebo group (p
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(89)90003-2